Invivyd (NASDAQ:IVVD) versus Stoke Therapeutics (NASDAQ:STOK) Head to Head Review

Stoke Therapeutics (NASDAQ:STOK) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Valuation and Earnings

This table compares Stoke Therapeutics and Invivyd”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42 million	8.92	-$6.89 million	($3.34)	-7.63
Invivyd	$53.43 million	5.24	-$52.49 million	($0.33)	-2.88

Stoke Therapeutics has higher revenue and earnings than Invivyd. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stoke Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Institutional & Insider Ownership

70.4% of Invivyd shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by company insiders. Comparatively, 12.2% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stoke Therapeutics and Invivyd’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Invivyd	-183.90%	-59.73%	-48.97%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Stoke Therapeutics and Invivyd, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	0	10	0	2.82
Invivyd	1	2	3	0	2.33

Stoke Therapeutics presently has a consensus price target of $44.25, suggesting a potential upside of 73.53%. Invivyd has a consensus price target of $8.00, suggesting a potential upside of 742.11%. Given Invivyd’s higher probable upside, analysts plainly believe Invivyd is more favorable than Stoke Therapeutics.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.